Adult survivors of pediatric cancer who underwent brain irradiation at risk for hormone deficiencies
the ONA take:
According to a new study published in the Journal of Clinical Oncology, researchers at St. Jude Children's Research Hospital in Memphis, Tennessee, have found that adult survivors of pediatric cancer are at risk for developing pituitary hormone deficiencies that may worsen their health and quality of life.
For the study, researchers analyzed data from 748 adults survivors of pediatric leukemia, brain, and other cancers that had received brain irradiation as part of their treatment in order to determine the long-term effect of the treatment on function of the pituitary gland.
Results showed that 51.4% of adult survivors were deficient in at least one of the hormones studied and 10.9% of survivors had multiple hormone deficiencies. The most common hormone deficiency involved gonadotropins, which play a role in fertility and reproduction.
Researchers also found that patients with those hormone deficiencies were more likely to be undiagnosed, and those were untreated were more likely to experience poor fitness, muscle weakness, heart disease risk factors, and other factors linked with an elevated risk of frailty and decreased mortality.
The authors note that additional research is warranted to to help manage patients with growth hormone deficiency.
Adult survivors of pediatric cancer are at risk for developing pituitary hormone deficiencies that may worsen their health and quality of life.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Women Treated for DCIS Have Slightly Lower Risk for All-Cause Mortality
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|